Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program ; day:15 ; month:2 ; year:2024 ; pages:1-10
Bone marrow transplantation ; (15.2.2024), 1-10
- Creator
-
Pattipaka, Thirupathi
Sarp, Séverine
Nakhaei, Peyman
Güneş, Sibel
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41409-024-02207-4
- URN
-
urn:nbn:de:101:1-2404230819418.795615612851
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Pattipaka, Thirupathi
- Sarp, Séverine
- Nakhaei, Peyman
- Güneş, Sibel
- SpringerLink (Online service)
Other Objects (12)
Clinical and diagnostic pathology of graft versus host disease (GvHD)
Photopheresebehandlung bei chronischer Graft-versus-Host-Erkrankung (GvHD): retrospektive Analyse eines standardisierten klinischen Evaluationsschemas mit Fokus auf die kutane GvHD
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
NFATc3 in der akuten GvHD
Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
Established and Emerging Treatments of Skin GvHD
18F-FDG-PET-MRI for the assessment of acute intestinal graft-versus-host-disease (GvHD)
18F-FDG-PET-MRI for the assessment of acute intestinal graft-versus-host-disease (GvHD)
Retrospektive Untersuchung der Graft versus Host Disease (GvHD), insbesondere an der Lunge, von Patienten nach Stammzelltransplantation
Rolle verschiedener T-Zell-Transkriptionsfaktoren in der akuten GvHD und GvL
Risikofaktoren für die akute GvHD nach allogener Stammzelltransplantation
Clinical and diagnostic pathology of graft versus host disease (GvHD)
Photopheresebehandlung bei chronischer Graft-versus-Host-Erkrankung (GvHD): retrospektive Analyse eines standardisierten klinischen Evaluationsschemas mit Fokus auf die kutane GvHD
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
NFATc3 in der akuten GvHD
Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
Established and Emerging Treatments of Skin GvHD
18F-FDG-PET-MRI for the assessment of acute intestinal graft-versus-host-disease (GvHD)
18F-FDG-PET-MRI for the assessment of acute intestinal graft-versus-host-disease (GvHD)
Retrospektive Untersuchung der Graft versus Host Disease (GvHD), insbesondere an der Lunge, von Patienten nach Stammzelltransplantation
Rolle verschiedener T-Zell-Transkriptionsfaktoren in der akuten GvHD und GvL
Risikofaktoren für die akute GvHD nach allogener Stammzelltransplantation
Clinical and diagnostic pathology of graft versus host disease (GvHD)
Photopheresebehandlung bei chronischer Graft-versus-Host-Erkrankung (GvHD): retrospektive Analyse eines standardisierten klinischen Evaluationsschemas mit Fokus auf die kutane GvHD
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
NFATc3 in der akuten GvHD
Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
Established and Emerging Treatments of Skin GvHD
18F-FDG-PET-MRI for the assessment of acute intestinal graft-versus-host-disease (GvHD)
18F-FDG-PET-MRI for the assessment of acute intestinal graft-versus-host-disease (GvHD)
Retrospektive Untersuchung der Graft versus Host Disease (GvHD), insbesondere an der Lunge, von Patienten nach Stammzelltransplantation
Rolle verschiedener T-Zell-Transkriptionsfaktoren in der akuten GvHD und GvL